A covalent KRASG12C inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

RMC-6291

Item No. 42174

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(3S)-N1-[N-[[1-[4-(dimethylamino)-4-methyl-1-oxo-2-pentyn-1-yl]-4-fluoro-4-piperidinyl]carbonyl]-N-methyl-L-valyl-3-[4-[(2R)-1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-[2-[(1S)-1-methoxyethyl]-3-pyridinyl]-1H-indol-5-yl]-2-morpholinyl]-L-alanyl]hexahydro-3-pyridazinecarboxylic acid, (3→2)-lactone
CAS Number
2641998-63-0
Molecular Formula
C55H78FN9O8
Formula Weight
1012.3
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
Acetonitrile: Slightly soluble: 0.1-1 mg/mlDMSO: Sparingly soluble: 1-10 mg/ml
SMILES
O=C([C@H](CCC1)NN1C([C@H](C[C@H]2CN3CCO2)NC([C@H](C(C)C)N(C)C(C4(F)CCN(C(C#CC(C)(C)N(C)C)=O)CC4)=O)=O)=O)OCC(C)(C)CC5=[C@@]([C@@]6=C([C@H](C)OC)N=CC=C6)N(CC)C7=C5C=C3C=C7
InChi Code
InChI=1S/C55H78FN9O8/c1-13-64-44-19-18-37-30-40(44)41(48(64)39-16-14-24-57-46(39)36(4)71-12)32-53(5,6)34-73-51(69)42-17-15-25-65(59-42)50(68)43(31-38-33-63(37)28-29-72-38)58-49(67)47(35(2)3)61(11)52(70)55(56)22-26-62(27-23-55)45(66)20-21-54(7,8)60(9)10/h14,16,18-19,24,30,35-36,38,42-43,47,59H,13,15,17,22-23,25-29,31-34H2,1-12H3,(H,58,67)/t36-,38-,42-,43-,47-/m0/s1
InChi Key
HJNFYLSFWYRSHS-CMZSUCOPSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $98

    Add

    5 mg

    $270

    Add

    10 mg

    $490

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    RMC-6291 is a covalent inhibitor of KRAS containing a glycine-to-cysteine mutation at position 12 (KRASG12C).1 It binds to KRASG12C and prevents KRASG12C-induced signaling via recruitment of peptidyl-prolyl cis-trans isomerase A (PPIase A), also known as cyclophilin A (CypA). It decreases the proliferation of 15 cancer cell lines expressing KRASG12C (median EC50 = 0.11 nM) and induces apoptosis in NCI H358 non-small cell lung cancer (NSCLC) cells. RMC-6291 (10-200 mg/kg per day) reduces tumor volume in an NCI H358 mouse xenograft model.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Schulze, C.J., Seamon, K.J., Zhao, Y., et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science 381(6659), 794-799 (2023).